Mounjaro vs Wegovy: Key Similarities & Differences

In recent years, the UK has seen a surge in interest in weight loss medications. Two standout options that have garnered significant attention are Mounjaro and Wegovy. Both medications offer promising results for individuals struggling with obesity and overweight. In this blog post, we’ll compare Mounjaro vs Wegovy for weight loss to help you make an informed decision about which might be the right choice for you.

Understanding GLP-1 and GIP

GLP-1 (Glucagon-Like Peptide-1) and GIP (Gastric Inhibitory Polypeptide) are two hormones produced in the intestines that play a crucial role in regulating blood sugar, appetite, and digestion. Both Wegovy and Mounjaro are designed to mimic the effects of these hormones, leading to weight loss and improved metabolic health.

Therefore, Wegovy and Mounjaro harnesses the power of GLP-1 and GIP

• Wegovy: Wegovy is a GLP-1 receptor agonist, which means it mimics the effects of GLP-1 in the body.
• Mounjaro: Mounjaro is a dual GLP-1 and GIP receptor agonist, meaning it activates both GLP-1 and GIP receptors.
• Leading to Weight Loss Benefits: By targeting these hormones, both medications can help promote weight loss by reducing appetite, improving blood sugar control, and slowing down stomach emptying.

Both the medications are approved and authorised by The MHRA and NICE for weight management in the UK. Wegovy became accessible in September 2023 for individuals with obesity, including some with diabetes. Mounjaro was subsequently recommended by NICE in June 2024 for those with overweight or obesity.

How does Mounjaro and Wegovy work?

Both Wegovy (semaglutide) and Mounjaro (tirzepatide)\ are both GLP-1 receptor agonists, meaning they mimic the effects of GLP-1 in the body. However, Mounjaro also targets the GIP receptor.

GLP-1:

• Appetite Suppression: GLP-1 helps reduce appetite by signalling the brain that you are full.
• Slowed Stomach Emptying: It slows down the rate at which food is emptied from the stomach, leading to a feeling of fullness for longer.
• Improved Blood Sugar Control: GLP-1 also helps regulate blood sugar levels by stimulating insulin production.

GIP:

• Insulin Production: GIP stimulates the release of insulin, which helps lower blood sugar levels.
• Appetite Regulation: While not as directly involved in appetite suppression as GLP-1, GIP can contribute to overall metabolic regulation.

Mounjaro vs Wegovy: Key Differences

Please note: While these are general comparisons, individual experiences may vary. While both Wegovy and Mounjaro are effective for weight loss, the choice between them may depend on individual factors such as side effects, cost etc. It’s essential to consult with a healthcare professional to determine which medication is best suited for your specific needs.

Feature	Wegovy	Mounjaro
Active Ingredient	Semaglutide	Tirzepatide
Mechanism of Action	GLP-1 receptor agonist	GLP-1 and GIP receptor agonist
Administration	Weekly injection	Weekly injection
Initial Dose	0.25mg	2.5mg
Maximum Dose	2.4mg	15mg
Significant Weight Loss	Up to 15%	Up to 22%

Mounjaro vs Wegovy: Key Similarities

Both Wegovy (semaglutide) and Mounjaro (tirzepatide) work in slightly different ways, but they share several key similarities:

1. Mechanism of Action:

• Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Both medications stimulate the GLP-1 receptor, a hormone that helps regulate appetite, blood sugar, and insulin production.
• Weight Loss: By mimicking the effects of GLP-1, these medications can help reduce appetite, increase feelings of fullness, and slow down the emptying of the stomach.

2. Efficacy for Weight Loss:

• Significant Weight Loss: Both Wegovy and Mounjaro have been shown to lead to substantial weight loss in clinical trials.
• Improved Health Outcomes: Beyond weight loss, these medications can also help improve blood sugar control, blood pressure, and cholesterol levels.

3. Administration:

• Weekly Injections: Both Wegovy and Mounjaro are administered as weekly injections. This makes them convenient for many patients.

4. Approval and Accessibility:

• NHS Availability: Both medications have been approved for use in the UK and are available through the NHS for eligible patients.
• Prescriptions: You’ll need a prescription from a healthcare professional to obtain either medication.

While Wegovy and Mounjaro share these similarities, it’s important to note that they also have some differences. These differences may impact their effectiveness and side effects for individual patients.

Dosage Progression of Wegovy and Mounjaro

Wegovy (semaglutide)

• Starting Dose: 0.25 mg
• Dose Increases: Doses are increased every four weeks, reaching a maximum of 2.4 mg.
• Administration: Each dose is administered in a separate pen.

Mounjaro (tirzepatide)

• Starting Dose: 2.5 mg
• Dose Increases: Doses are increased every four weeks, reaching a maximum of 15 mg.
• Administration: Each dose is administered in a separate pen.

Key Differences:

• Starting Dose: Mounjaro starts at a higher dose than Wegovy.
• Maximum Dose: Mounjaro has a higher maximum dose, allowing for more individualised treatment.

It’s important to note that your healthcare professional will determine the appropriate dosage for you based on your individual needs and response to the medication. The dosage progression may vary depending on factors such as your weight, medical history, and how well you tolerate the medication.

Managing Wegovy and Mounjaro Side Effects

Both Wegovy and Mounjaro can cause side effects, particularly during the initial stages of treatment. However, many of these side effects are manageable and often improve over time. Here are some tips for managing side effects:

Common Side Effects

• Nausea and Vomiting:

Start slowly: Begin with a lower dose and gradually increase it to minimise initial discomfort.

Eat small, frequent meals: This can help prevent nausea.

Avoid triggers: Identify foods or beverages that exacerbate nausea and limit your intake.

• Diarrhoea or Constipation:

• Abdominal Pain:

Take over-the-counter pain relievers: If the pain is severe, consult your clinician.

Avoid irritating foods: Identify foods that trigger abdominal pain and limit your intake.

Important Note:

• Communicate with your clinician: If you’re experiencing significant side effects, discuss them with your healthcare professional. They may be able to adjust your dosage or recommend alternative strategies.
• Be patient: Side effects often improve over time as your body adapts to the medication.
• Consider lifestyle changes: Adopting a healthy diet and regular exercise can help manage side effects and improve overall well-being.

Remember: Everyone’s experience with side effects is unique. If you’re concerned about the side effects you’re experiencing, don’t hesitate to reach out to your healthcare professional for guidance and support.

Switching Between Mounjaro and Wegovy

Deciding whether to switch between Mounjaro and Wegovy is a personal decision that should be made in consultation with your healthcare professional. Both medications are effective for weight loss, but they have different mechanisms of action and may have varying side effects.

Factors to consider when switching medications:

• Individual response: How well have you responded to your current medication? Have you achieved your desired weight loss goals? Are you experiencing significant side effects?
• Side effects: Some individuals may experience fewer or different side effects with one medication compared to the other.
• Cost: Both Mounjaro and Wegovy can be expensive, depending on the dosages.
• Lifestyle: Your lifestyle and preferences may influence your choice. 

It’s important to note that switching medications can sometimes be a trial-and-error process. What works well for one person may not work as well for another.

If you’re considering switching between Mounjaro and Wegovy, it’s essential to discuss your options with your healthcare professional.

Can you get Mounjaro and Wegovy on the NHS?

Yes, you can potentially get Mounjaro and Wegovy on the NHS. However, there are a few conditions:   

• Eligibility: You’ll likely need to meet specific criteria, such as having a BMI of 35 or higher, or a BMI of 30 with at least one obesity-related condition.   
• Referral: Your GP will need to refer you to a specialist weight management service.
• Availability: The availability of these medications may vary depending on NHS’s current policies.

It’s important to consult with your healthcare professional to discuss your options and determine if you’re eligible for these medications. They can provide you with more specific information and guidance.

Where to buy weight loss injections in the UK?

Prescription weight loss medications can vary in cost depending on dosage. We at Priman are committed to offering weight loss injections at competitive rates to support your weight loss journey.

Which one is right for you? 

The best choice depends on your individual needs and preferences. Factors to consider include:

• Your weight loss goals: If you’re looking for maximum weight loss, Mounjaro might be a better option.
• Your tolerance for side effects: If you’re sensitive to gastrointestinal issues, you may want to weigh the benefits and risks of both medications.
• Your budget: Both medications can be expensive, so it’s important to consider your health insurance coverage and out-of-pocket costs.

Key Takeaway

GLP-1 and GIP are key hormones involved in weight regulation. Wegovy and Mounjaro, by acting on these hormones, offer effective options for individuals seeking to manage their weight and improve their overall health combined with diet and exercise. 

It’s crucial to consult with a healthcare professional to determine the best weight loss medication for you. They can assess your individual needs, discuss the potential benefits and risks of Mounjaro and Wegovy, and help you make an informed decision.

Start Your Weight Loss Journey Today with Priman.

References 

Jastreboff, A. M. et al. (2022) “Tirzepatide once weekly for the treatment of obesity,” The New England journal of medicine, 387(3), pp. 205–216. doi: 10.1056/nejmoa2206038. 

Mounjaro (tirzepatide) (2024) Diabetes UK. Available at: https://www.diabetes.org.uk/guide-to-diabetes/managing-your-diabetes/treating-your-diabetes/tablets-and-medication/glp-1/mounjaro 

Samms, R. J., Coghlan, M. P. and Sloop, K. W. (2020) “How may GIP enhance the therapeutic efficacy of GLP-1?,” Trends in endocrinology and metabolism: TEM, 31(6), pp. 410–421. doi: 10.1016/j.tem.2020.02.006.

Singh, G., Krauthamer, M. and Bjalme-Evans, M. (2022) “Wegovy (semaglutide): A new weight loss drug for chronic weight management,” Journal of investigative medicine: the official publication of the American Federation for Clinical Research, 70(1), pp. 5–13. doi: 10.1136/jim-2021-001952.

Wadden, T. A. et al. (2023) “Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial,” Nature medicine, 29(11), pp. 2909–2918. doi: 10.1038/s41591-023-02597-w.

Wegovy (2024) Diabetes UK. Available at: https://www.diabetes.org.uk/guide-to-diabetes/managing-your-diabetes/treating-your-diabetes/tablets-and-medication/glp-1/semaglutide/wegovy

Wilding, J. P. H. et al. (2021) “Once-weekly semaglutide in adults with overweight or obesity,” The New England journal of medicine, 384(11), pp. 989–1002. doi: 10.1056/nejmoa2032183.